^
Association details:
| Biomarker: | RYR1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer A Meta-analysis and Individual Patient–Level Analysis
Excerpt:
The best checkpoint blockade strategy was first-line pembrolizumab with platinum-based chemotherapy...RYR1 or MGAM mutations were significantly associated with concomitantly increased durable clinical benefits (RYR1: durable clinical benefit [DCB], 12 of 51 patients [24%]; no durable benefit [NDB], 2 of 55 patients [4%]; P < .001; MGAM: DCB, 12 of 51 patients [24%]...Of note, we further identified novel genes, such as RYR1 and MGAM, in which mutations were significantly associated with increased response and higher PD-L1 expression and TMB, indicating that these genes may contribute to IC infiltration...
DOI:
10.1001/jamanetworkopen.2019.6879
Trial ID:
